Olmutinib

奥莫替尼

Report date: 2026/03/23 20:03:44
NME

Base Information

Drug NameOlmutinib
Drug Alias NameOlitaBI-1482694HM-61713BHM-61713ZL-2303
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR T790M inhibitors
TargetsEGFR T790M
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2016/05/17
Country/TerritoryBosnia and HerzegovinaBulgariaCanada +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaDiscontinued
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co LtdJiangsu Hansoh Pharmaceutical Group Co Ltd
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgZai Lab (Shanghai) Co LtdKonkuk University Medical Center
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeL01EB06
Related LinksDrugBankKEGG